Kazia Therapeutics (KZIA)

Executive Summary

Kazia Therapeutics is an Australian oncology-focused biotechnology company primarily developing paxalisib, a brain-penetrant PI3K/AKT/mTOR inhibitor, for glioblastoma (GBM) and other brain cancers. Paxalisib has received FDA Orphan Drug and Fast Track designations, reflecting its potential in a high-unmet-need indication. The drug is currently being evaluated in a global Phase 2/3 GBM AGILE study, with interim data anticipated in late 2026. Kazia also has an early-stage asset, EVT801, a VEGFR3 inhibitor for advanced solid tumors, which is in Phase 1 dose escalation. The company's strategy involves in-licensing differentiated candidates and advancing them through clinical trials to generate data supporting regulatory approval and commercialization. As a clinical-stage public entity (ASX: KZIA), Kazia operates with a focus on generating value through pipeline progression and potential partnerships.

Upcoming Catalysts (preview)

• Q4 2026Paxalisib GBM AGILE Phase 2/3 Interim Efficacy Data70% success
• Q3 2026EVT801 Phase 1 Dose Escalation Update50% success
• Q2 2027Potential Licensing or Partnership Deal for Paxalisib30% success